Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate
The objective of this Phase II clinical trial was to determine the effects of chronic GM-CSF dosing on PSA levels in men with hormone-refractory or hormone-naïve prostate cancer. Six hormone-refractory and 10 hormone-naïve patients were recruited from an institutional practice and were treated with...
Main Authors: | Robert J. Amato D.O., Joan Hernandez-Mcclain |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S566 |
Similar Items
-
TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
by: Gautam Kumar
Published: (2020-01-01) -
Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer
by: Hiroyoshi Suzuki, et al.
Published: (2019-10-01) -
CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER
by: Ya. V. Gridneva, et al.
Published: (2014-08-01) -
CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER
by: Ya. V. Gridneva, et al.
Published: (2014-08-01) -
Pathogenesis of prostate cancer and hormone refractory prostate cancer
by: J S Girling, et al.
Published: (2007-01-01)